About Enyo Pharma
Enyo Pharma is a company based in Lyon (France) founded in 2014. Enyo Pharma has raised $120.34 million across 8 funding rounds from investors including Orbimed, Bpifrance and Andera Partners. Enyo Pharma offers products and services including Vonafexor. Enyo Pharma operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enyo Pharma Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$120.34 M (USD)
in 8 rounds
-
Latest Funding Round
$6.87 M (USD), Series C
Jun 12, 2025
-
Investors
Orbimed
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enyo Pharma
Enyo Pharma offers a comprehensive portfolio of products and services, including Vonafexor.
Small molecule treating kidney diseases like Alport Syndrome
People of Enyo Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Enyo Pharma
Enyo Pharma has successfully raised a total of $120.34M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $6.87 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enyo Pharma
Enyo Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Bpifrance and Andera Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Locked | Locked | Locked |
Investor details for Enyo Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enyo Pharma
Investment portfolio details for Enyo Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enyo Pharma
Detailed financials for Enyo Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enyo Pharma Comparisons
Peer comparison for Enyo Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enyo Pharma
Enyo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for metabolic disorders are developed.
|
Detailed competitors of Enyo Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enyo Pharma
Complete news archive for Enyo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enyo Pharma
Enyo Pharma was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Enyo Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Enyo Pharma is a funded company, having raised a total of $120.34M across 8 funding rounds to date.
Enyo Pharma was founded in 2014 and is based in Lyon, France. Therapeutics targeting diseases associated with impaired kidney function are developed by the company within the pharmaceutical sector. Operations focus on small molecules such as VONAFEXOR, which exhibits fibrolytic and anti-inflammatory effects in both kidney and liver tissues. The companys activities center on advancing treatments for organ-specific conditions.
Enyo Pharma's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Enyo Pharma offers Vonafexor.
Enyo Pharma has 10 investors. Key investors include Orbimed, Bpifrance, Andera Partners, European Union, and Inserm Transfert.